Huawei Asks U.S. Court to Declare Defense Bill 'Unconstitutional'
HONG KONG (Reuters) - China's Huawei Technologies Co. Ltd. has filed a motion for summary judgment in its lawsuit against the U.S. government, according to a court filing in the United States, in the telecoms equipment maker's latest attempt to fight sanctions from Washington that threaten to push it out of global markets.
The motion filed late Tuesday in the U.S. District Court for the Eastern District of Texas asks to declare the 2019 National Defense Authorization Act (NDAA) unconstitutional, in an update to the lawsuit against the act that the Chinese company started in March.
The NDAA bill, passed into law by the U.S. Congress last summer, places a broad ban on federal agencies and their contractors from using Huawei equipment on national security grounds, citing the company's ties with the Chinese government.
Huawei has repeatedly denied it is controlled by the Chinese government, military or intelligence services.
The world's largest telecom network gear maker has since faced even greater sanctions as the U.S. commerce department on May 16 put the firm on a trade blacklist that bans companies from doing business with Huawei, in a move which immediately disrupted the global tech sector.
The ban comes amid an escalating trade dispute between the world's two biggest economies.
Huawei, which has been given a 90-day reprieve from the ban, has denied that its products pose a security threat and protested Washington's attempts to limit its business.
Song Liuping, Huawei's chief legal officer, wrote in the Wall Street Journal on Monday that the law is a violation of due process as it "directly and permanently applies to Huawei without opportunity for rebuttal or escape".
"This is the tyranny of 'trial by legislature' that the U.S. Constitution prohibits," Song wrote.
China's Toy Retailer Pop Mart is Considering a Hong Kong IPO
Huya Reports 47% Increase in First Quarter Revenue
GSX Rebuts Short Seller Report; Shares Continue to Slide
iClick Interactive Announces Strategic Collaboration with Tencent
Ruipeng Pet Clinic Seeks New Funding Ahead of IPO
CANbridge Pharmaceuticals is Reportedly Seeking Hong Kong IPO